Ask around any peptide procurement circle in Business Bay or among the biotech researchers operating out of co-working labs in Dubai Marina, and you will hear "tesa" used as a catch-all noun. Tesa powder. Generic tesa vials. Tesa-rel. Modified GHRH. GHRH 1-44 analogue. The terms are used interchangeably, as though they describe the same research compound. They do not, and the conflation is doing serious damage to research data quality across UAE.
The UAE research peptides market expanded rapidly through 2024 and 2025. Labs in Abu Dhabi's health district, independent researchers in Sharjah, and procurement teams at biotech firms in DIFC are all importing peptides at volume. That growth has outpaced supplier accountability. A tier of vendor has emerged that sells anything beginning with "tesa" under the assumption that buyers either cannot tell the difference or will not check. Generic tesa compounds are frequently sourced from bulk synthesis operations with no sequence confirmation, no endotoxin testing, and HPLC certificates that cover a pooled production lot rather than the specific batch shipped to you.
The practical consequence is not abstract. If your GHRH receptor binding assay, adipose tissue model, or GH pulse kinetics study is contextualised against the Falutz or Stanley clinical publications, you need the exact molecular entity those trials used. A truncated GHRH fragment, a crude analogue with 78% purity, or a product missing the N-terminal hexenoic acid modification is a different molecule with a different receptor binding profile, a different plasma half-life, and different in-vitro kinetics. Feeding it into your protocol does not produce comparable data. It produces noise dressed up as signal.
This is not a marginal concern for perfectionist researchers. It is the central question in peptide sourcing: are you working with a characterised compound or an unknown variable? This guide provides a framework for answering that question definitively when buying tesamorelin in UAE, and explains why REVIVE LAB UAE is the sourcing answer for researchers who need a confirmed answer.
Tesamorelin is not a synonym for synthetic GHRH and it is not a descriptor for the class of GHRH analogues. It is a single, precisely defined compound: the trans-3-hexenoic acid conjugate of human growth hormone-releasing hormone spanning residues 1 through 44, with a C-terminal amide modification — commonly written as GHRH(1-44)-NH₂-hexenoic acid. Its confirmed molecular weight is 5135.9 Da. Every one of these structural features is load-bearing for research validity.
The full 44-residue sequence is significant. Many "generic GHRH" and "generic tesa" research products are synthesised as truncated fragments, most commonly GHRH(1-29), following the well-documented observation that the first 29 residues of GHRH retain growth hormone secretagogue activity at the pituitary receptor. But GHRH(1-29) and tesamorelin are not interchangeable in any research model designed to investigate the specific pharmacokinetics, metabolic stability, or receptor saturation characteristics of tesamorelin. Residues 30 through 44 contribute to the peptide's overall conformation and secondary receptor interactions. Truncating at position 29 eliminates those contributions and changes the pharmacodynamic profile.
The trans-3-hexenoic acid conjugation at the N-terminus is equally critical. This modification confers substantially improved resistance to dipeptidyl peptidase IV (DPP-IV) cleavage relative to native GHRH, which is metabolised rapidly by DPP-IV cleavage at the His-Ala bond at positions 1-2. In any research model that involves exposure to serum, plasma, or living cells with endogenous DPP-IV activity, a generic GHRH product lacking this modification will have a fundamentally different stability profile. The time-course of receptor activation changes. The apparent potency at given concentrations changes. The dose-response curve shifts. None of these shifts can be corrected in post-processing — they must be controlled at the sourcing stage.
When vendors in the UAE market sell "tesa," "tesa compound," or "generic GHRH 1-44," researchers should ask a direct question: does your CoA confirm the presence of the trans-3-hexenoic acid N-terminal modification via mass spectrometry, with the observed molecular ion at 5135.9 Da? If the answer is no, or if the vendor does not understand the question, the product is not tesamorelin.
Tesamorelin carries one of the most substantive human-study records of any GHRH analogue available for research reference today. This matters for UAE researchers not because REVIVE LAB UAE supplies a pharmaceutical product — it does not, all products are supplied for laboratory and scientific research purposes only — but because the published clinical literature defines the mechanistic framework against which GHRH analogue research models are designed and interpreted. If your assay design is derived from, or benchmarked against, that literature, molecular fidelity to the studied compound is non-negotiable.
Falutz et al. published in the New England Journal of Medicine in 2007 the foundational controlled trial demonstrating statistically significant reductions in visceral adipose tissue in HIV-associated lipodystrophy subjects receiving tesamorelin versus placebo. The methodology, the primary endpoints, and the dose parameters from that publication have since become the canonical reference for GHRH analogue research in adipose tissue biology. Any lab working on GH-axis modulation, visceral fat depot biology, or GHRH receptor signal transduction is working in the downstream context of that trial.
The continuation study from Falutz et al. in the New England Journal of Medicine in 2010 extended the evidence base across a longer observation window, addressing questions about receptor adaptation, sustained GH pulse modulation, and the reversibility of observed effects following compound withdrawal. These are precisely the experimental questions that drive in-vitro time-series assay design: what happens at the receptor level during sustained GHRH analogue exposure, and what is the recovery kinetics after removal? Research designed to model those questions needs the compound whose kinetics are documented — tesamorelin — not a generic fragment with an uncharacterised stability profile.
Stanley et al. published in JAMA in 2014 provided an independent replication of the visceral fat signal in a separate study design, strengthening the mechanistic evidence for tesamorelin's specific adipose tissue effects through the GH/IGF-1 axis. The 2019 publication from Stanley et al. in The Lancet HIV delivered the longest available follow-up data for the tesamorelin mechanism, addressing durability questions that remain active areas of investigation in metabolic biology research. Together, these four publications represent the evidentiary spine of tesamorelin research interest. Generic tesa compounds have no equivalent literature. They are not the same molecule as the one studied.
The CoA is the document that separates verified tesamorelin from labelled guesswork. Every peptide vendor in the UAE market claims to provide one. The question researchers must ask is not whether a CoA exists — it is what the CoA actually confirms. A one-page HPLC chromatogram from an unspecified batch, printed with the product name "tesamorelin 5mg," is not a certificate of analysis for the purposes of controlled research. Here is what a minimal-standard CoA for research-grade tesamorelin must contain:
Generic tesa compound vendors in the UAE and international grey market routinely provide CoAs that confirm only HPLC purity, often on a pooled lot, without mass spectrometry identity confirmation. Mass spec data is expensive to run and would immediately reveal sequence truncation or missing modifications in lower-quality products. Its absence from a tesamorelin CoA is not an oversight — it is a red flag.
Researchers procuring peptides UAE from REVIVE LAB UAE receive a batch-specific CoA covering HPLC purity (98% minimum threshold), ESI mass spectrometry confirmation of the 5135.9 Da molecular ion, and endotoxin results. Procurement teams at research institutions in Downtown Dubai, university-affiliated labs in Sharjah, and private research operations in Abu Dhabi's healthcare district all receive the same documentation package with every order. There are no exceptions for bulk orders and no substitution of pooled-batch certificates for batch-specific ones.
The table below summarises the key differentiators UAE researchers should evaluate before committing to any tesamorelin order. The left column reflects what REVIVE LAB UAE delivers. The right column reflects the common reality of generic tesa supply found in the grey-market peptides Dubai and international broker landscape.
| Research Parameter | Verified Tesamorelin (REVIVE LAB UAE) | Generic "Tesa" Compounds |
|---|---|---|
| Molecular identity | GHRH(1-44)-NH₂ + trans-3-hexenoic acid, MW 5135.9 Da confirmed | Unknown — may be GHRH(1-29), truncated fragment, or crude analogue |
| HPLC purity | ≥98% (batch-specific chromatogram) | Often unstated, pooled-batch, or below 95% |
| Mass spectrometry confirmation | ESI-MS on every production batch | Rarely provided; hexenoic acid modification unverified |
| Endotoxin testing | <1 EU/mg via LAL assay, batch-specific | Typically absent from documentation |
| Vial format | 5mg and 10mg lyophilised, amber borosilicate, foil crimped | Inconsistent — bulk powder common, vials without specification |
| UAE delivery speed | Same-day Dubai, 24h UAE-wide (Abu Dhabi, Sharjah, northern emirates) | International shipping, 7–21 day lead times, customs exposure |
| Cold-chain packaging | Insulated packaging for UAE summer temperatures (June–September) | Standard international packaging, no UAE climate consideration |
| Alignment with published research literature | Direct — Falutz 2007/2010 NEJM, Stanley 2014 JAMA, Stanley 2019 Lancet HIV | Questionable to none — different molecular entity, no equivalent literature |
| Payment options in UAE | Cash on delivery Dubai, bank transfer, Binance Pay USDT TRC20 | International wire transfer only, no local UAE payment methods |
Whether you are procuring for a lab in Jumeirah, a research unit attached to a university in Sharjah, or a private biotech operation in Palm Jumeirah, this checklist should function as your minimum due-diligence standard before committing to any tesamorelin supplier. It is not bureaucratic compliance — it is research validity.
REVIVE LAB UAE stocks tesamorelin in two formats: 5mg lyophilised vials and 10mg lyophilised vials, produced under GMP-aligned synthesis conditions and filled into amber borosilicate vials with foil-crimped stoppers. Both formats are accompanied at dispatch by batch-specific certificates of analysis that include HPLC purity (minimum 98% threshold), ESI mass spectrometry confirmation of the tesamorelin molecular ion at 5135.9 Da, and LAL endotoxin assay results. All vials are stored under controlled conditions at our Dubai-based fulfilment facility until dispatch.
For researchers designing GHRH-analogue studies and seeking to contextualise their work against the published clinical literature, the studies referenced in this article employed GHRH analogue dose parameters in the 1–2 mg per day range as a research-use reference point. This is noted for academic orientation only and does not represent dosing guidance of any kind. Our 5mg and 10mg vial options are designed to accommodate multi-point dose-response experimental designs and extended time-series protocols without mid-study restocking interruptions for UAE-based research operations.
Dispatch logistics: orders placed before 12:00 GST receive same-day dispatch. Dubai delivery zones — including Business Bay, Downtown Dubai, DIFC, Dubai Marina, JBR, Palm Jumeirah, Al Barsha, and Jumeirah — typically receive delivery within 3 to 5 hours of dispatch. Abu Dhabi, Sharjah, and northern emirates addresses are covered within 24 hours. All parcels are shipped in unmarked, discreet outer packaging. No peptide names, no REVIVE LAB UAE branding, and no identifying product terminology appear on the outer parcel. This applies to all orders without exception — individual vials and bulk research quantities alike.
Payment: cash on delivery is available for Dubai addresses. UAE bank transfer is accepted for researchers who prefer electronic payment. Binance Pay (USDT TRC20) is available with a 5% pre-pay discount applied automatically at checkout. For institutional procurement, volume research orders, or researchers with specific documentation requirements for their facility, WhatsApp order management is available and our team responds within business hours.
REVIVE LAB UAE stocks tesamorelin 5mg and 10mg vials with same-day dispatch for orders placed before 12:00 GST from our Dubai fulfilment facility. Delivery covers all major Dubai zones — Marina, JBR, Business Bay, Downtown, DIFC, Palm Jumeirah, and Jumeirah — as well as Abu Dhabi and Sharjah within 24 hours. Every batch ships with a batch-specific CoA confirming HPLC purity at 98% minimum and ESI mass spectrometry verification of the 5135.9 Da molecular ion. Visit our tesamorelin product page to check live stock status and place an order.
Tesamorelin is a precisely characterised compound: the trans-3-hexenoic acid conjugate of human GHRH(1-44)-NH₂, with a confirmed molecular weight of 5135.9 Da. Generic tesa and tesa-rel compounds sold in the UAE and international peptide markets may omit the hexenoic acid N-terminal modification, truncate the amino acid sequence at residue 29, or simply lack verified purity and identity documentation — making them structurally non-equivalent to tesamorelin. For any research protocol contextualised against the Falutz 2007 or 2010 NEJM publications or the Stanley 2014 JAMA or 2019 Lancet HIV studies, using a generic fragment rather than confirmed tesamorelin renders results non-comparable to the published literature. The difference is not a technicality — it is a fundamental research validity issue.
Yes. Cash on delivery is available for all Dubai delivery addresses. REVIVE LAB UAE also accepts Binance Pay (USDT TRC20) with a 5% pre-pay discount, and UAE bank transfer. All orders are shipped in discreet, unmarked outer packaging with no peptide product names, REVIVE LAB UAE branding, or identifying content visible on the exterior of the parcel. For institutional or volume research procurement, contact our team via WhatsApp for documentation support and volume pricing options.